2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. PPAR
  5. PPAR Isoform
  6. PPAR Antagonist

PPAR Antagonist

PPAR Antagonists (7):

Cat. No. Product Name Effect Purity
  • HY-14166
    MK-886
    		Antagonist 99.77%
    MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.
  • HY-14166A
    MK-886 sodium salt
    		Antagonist
    MK-886 (L 663536) sodium salt is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 sodium salt is also a non-competitive PPARα antagonist and can induce apoptosis.
  • HY-120188
    CC618
    		Antagonist
    CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors.
  • HY-16578S
    GW9662-d5
    		Antagonist
    GW9662-d5 is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively[1][2].
  • HY-117727S
    Leriglitazone-d4
    		Antagonist
    Leriglitazone-d4 (MIN-102-d4; Hydroxypioglitazone-d4) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penatrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases.
  • HY-169070
    Anti-osteoporosis agent-10
    		Antagonist
    Anti-osteoporosis agent-10 is an osteoporosis inhibitor. Anti-osteoporosis agent-10 can suppress the generation of osteoclasts, with an IC50 of 0.042 μM. Anti-osteoporosis agent-10 also has antagonistic activity on PPARγ, with an EC50 value of 0.75 μM.
  • HY-155704
    Lyciumamide A
    		Antagonist
    DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC50 values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC50 value of 47.13 μM .